Background and Purpose-Despite overwhelming evidence for the benefits of anticoagulation in patients with brain ischemia and atrial fibrillation, vast underuse has been reported. Methods-Use of anticoagulation for secondary stroke prevention was assessed in the National Acute Stroke Israeli Survey registry (NASIS) of hospitalized patients with atrial fibrillation and acute brain ischemia. Logistic regression analysis was performed to evaluate the effects of clinical covariates on anticoagulation therapy at discharge, and anticoagulation use over time was assessed in subgroups of patients with identified barriers to anticoagulation utilization. Results-There were 1254 survivors of acute brain ischemia with atrial fibrillation (mean age 77.2±10.6 years; 57.7% female). Between 2004 and 2013, the proportion of patients discharged on anticoagulation increased from 55% to 76.2%, and among those without perceived contraindications from 70% to 96% (P<0.0001). Older age, greater stroke severity, earlier registry period, and presence of contraindications were independent predictors of withholding therapy. Increased anticoagulation use over the years was observed even in patients with barriers to anticoagulation use, including patients with potential contraindications (P<0.001). Conclusions-In survivors of acute brain ischemia with atrial fibrillation, we observed a substantial increase in anticoagulation utilization within less than a decade. This change was mainly driven by greater utilization of anticoagulation in subgroups with traditional clinical barriers to anticoagulation use, indicating a shift in physicians' perceptions of the risk-benefit ratio of anticoagulation.
A nticoagulation reduces the risk of stroke in atrial fibrillation (AF) and is associated with decreased stroke severity and improved outcome. [1] [2] [3] However, anticoagulation remains underused even in survivors of acute brain ischemia, [4] [5] [6] despite substantial efforts to raise awareness of its importance in secondary prevention. Against this background, we evaluated anticoagulation treatment patterns and the role of perceived clinical barriers to anticoagulation in patients hospitalized with acute brain ischemia associated with AF over almost a decade in the National Acute Stroke Israeli Survey registry (NASIS), a nationwide prospective survey of patients hospitalized with acute brain ischemia. 
Methods
NASIS is conducted triennially over a period of 2 consecutive months in all medical, surgical, and intensive care departments of all 28 hospitals operating in Israel. 6, 7 Data prospectively collected during all 4 surveys (2004-2013) were analyzed. Patients with primary intracerebral hemorrhage were excluded. Contraindications to anticoagulation were prespecified. 8, 9 Absolute contraindications included secondary hemorrhagic transformation, gastrointestinal or urinary hemorrhage, any major bleeding requiring ≥2 transfusions or a decrease in hemoglobin ≥2 g/dL, and severe thrombocytopenia (<50 000 per mL). Relative (potential) contraindications included poor functional state requiring discharge to nursing facility and dementia, recurrent falls, noncompliance and patient refusal, alcohol abuse and severe liver dysfunction, malignancy, severe renal failure (estimated glomerular filtration rate [eGFR]<30 mL min −1 1.73 m −2 ), and peptic disease.
Continuous variables are reported as mean and SD and categorical variables as percentages. A Cochran-Armitage test was performed to identify trends over time. Logistic regression analysis was performed to identify clinical covariates associated with nonuse (barriers) or use of anticoagulation at discharge. Odds ratios are reported with their 95% confidence interval. Significance level was set at P <0.05. Statistical analyses were performed using SAS version 9.4 (Cary, NC).
Results
Four registry periods lasting 2 months each were conducted between 2004 and 2013. During the cumulative observation period of 8 months, 1396 patients with acute brain ischemia (ischemic stroke or transient ischemic attack) and AF were hospitalized. A total of 1254 (89.8%) patients (aged 77.2±10.6 years, 57.7% female) survived to discharge. A total of 1219 patients (97.3%) had a known history of AF. Complete data were available in 1117 survivors (89%). Over the study period, there was a trend for an increase in age, prevalence of atherosclerotic risk factors, previous transient ischemic attack, and chronic kidney disease (online-only Data Supplement).
The proportion of patients discharged on anticoagulation increased substantially over the study period ( Figure 1A The odds of discharge on anticoagulation decreased with the presence of contraindication older age (≥75 years), and greater stroke severity (National Institutes of Health Stroke Scale [NIHSS] score of >10), and increased with a more recent registry period (Table) . The odds ratio for discharge on anticoagulation in 2013 was >3-fold higher compared with 2004. Anticoagulation use increased over time in all subgroups of patients with clinical barriers (Figure 2 ). In patients with greater stroke severity and in older patients, values even approached those of patients without any barriers to anticoagulation use. The largest increases were observed in patients with the most significant barrier to anticoagulation use (perceived contraindication) and in those with all 3 barriers (Figure 2 ).
Discussion
This study shows a sustained and substantial (38%) increase in the proportion of stroke survivors with AF discharged on anticoagulation in less than decade. In 2013, 76% of patients overall and 96% of patients without prespecified contraindications were discharged on anticoagulation. Because the prevalence of contraindications and anticoagulation use on admission remained essentially unchanged, this increase is solely attributable to increased rates of anticoagulation initiation, and thus improved guideline adherence, during the index hospitalization. Importantly, the increase in anticoagulation at discharge was particularly pronounced in patients with 
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model-identified barriers to anticoagulation utilization, such as presence of potential contraindications, more severe stroke, older age, individually or in combination ( Figure 2 ). Our data are in general agreement with those from the Get With The Guidelines (GWTG)-Stroke program 10 and the Danish Stroke Registry 11 and substantially better than those reported in the Western Finland FibStroke study 12 and recent data from the Chinese National Stroke Registry. 5 However, in contrast to GWTG-Stroke, a voluntary performance improvement program, and FibStroke, NASIS is a nationwide comprehensive registry of all Israeli hospitals, thus minimizing institution and patient selection bias. Reasons for withholding anticoagulation were similar to those reported in the quoted studies; however, stroke severity was not assessed in GWTGStroke, and none of the studies analyzed potential changes in treatment pattern over time within the clinically important subgroups of patients with barriers to anticoagulation use.
It is possible that participation in a registry itself may have improved our outcome measure because clinicians were aware that their therapeutic decisions were monitored (Hawthorne effect). 13 Performing regular surveys of clinical activity may therefore not just provide information but represent in itself a valuable intervention.
Conclusions
In survivors of acute brain ischemia with AF, a significant and substantial increase in anticoagulation utilization was observed within less than a decade. This change was mainly driven by greater utilization of anticoagulation in subgroups with traditional clinical barriers to anticoagulation use, indicating a shift in physicians' perceptions of the risk-benefit ratio of anticoagulation.
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